Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b/3 randomized double-blind placebo-controlled study of icotrokinra in moderate to severe active Crohn's disease
MOH_2025-09-21_014357Phase 3Recruiting
- Sponsor
- Johnson & Johnson
- Start
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in Crohn's disease (8 arms), sponsored by Johnson & Johnson. Started Sep 2025; status: recruiting.
02
Drugs
icotrokinra
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2025-09-21_014357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-21_014357.